Applied to docetaxel – trastuzumab immunoliposomes in a model of Her2+ breast cancer cell line, QFCM was successfully used to precise the optimal number of trastuzumab molecules to coat to achieve a maximal efficacy. The gene discussed is ERBB2; the disease is breast carcinoma.